CYP19A1 and hyperphosphatemia: Researchers demonstrated that prostatic hyperplasia is caused by using aromatase inhibitors to decrease oestrogen, leading to hyperphosphatemia and lowering dihydroxy vitamin D levels (Cheboub et al.